Dr. Mark Schroeder, MD

Medical Oncology Saint Louis, MO Male
NPI: 1255544680
Total Payments
$337,205
2024 Payments
$80,506
Companies
20
Transactions
184
Medicare Patients
3,952
Medicare Billing
$1.4M

Payment Breakdown by Category

Research$151,914 (45.1%)
Consulting$129,733 (38.5%)
Other$48,103 (14.3%)
Travel$5,736 (1.7%)
Food & Beverage$1,580 (0.5%)
Education$139.89 (0.0%)

Payments by Nature

Nature of Payment Amount Transactions Share
Unspecified $151,914 96 45.1%
Consulting Fee $129,733 26 38.5%
Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $48,103 14 14.3%
Travel and Lodging $5,736 19 1.7%
Food and Beverage $1,580 25 0.5%
Education $139.89 4 0.0%

Payments by Type

General
$185,292
88 transactions
Research
$151,914
96 transactions

Top Paying Companies

Company Total Records Latest Year
GlaxoSmithKline, LLC. $87,288 6 $0 (2024)
Ichnos Sciences Inc. $64,698 26 $0 (2023)
Novo Nordisk AS $47,663 49 $0 (2023)
IGI Inc $40,904 23 $0 (2024)
Incyte Corporation $20,910 12 $0 (2022)
PFIZER INC. $18,755 11 $0 (2019)
Takeda Pharmaceuticals U.S.A., Inc. $15,037 11 $0 (2019)
GENZYME CORPORATION $10,874 11 $0 (2024)
Merck Sharp & Dohme LLC $9,964 10 $0 (2022)
Amgen Inc. $5,558 10 $0 (2019)

Payment History by Year

Year Amount Transactions Top Company
2024 $80,506 28 IGI Inc ($40,904)
2023 $111,598 29 Ichnos Sciences Inc. ($64,698)
2022 $7,371 5 Stemline Therapeutics Inc. ($3,900)
2021 $10,838 12 Incyte Corporation ($5,000)
2020 $7,708 7 GENZYME CORPORATION ($3,259)
2019 $38,531 35 Takeda Pharmaceuticals U.S.A., Inc. ($11,737)
2018 $52,089 43 Novo Nordisk AS ($29,928)
2017 $28,566 25 Incyte Corporation ($9,023)

All Payment Transactions

184 individual payment records from CMS Open Payments — Page 1 of 8

Date Company Product Nature Form Amount Type
12/20/2024 IGI Inc — — Cash or cash equivalent $521.64 Research
Study: ISB 1442-101
12/20/2024 IGI Inc — — Cash or cash equivalent $521.64 Research
Study: ISB 1442-101
12/20/2024 IGI Inc — — Cash or cash equivalent $521.64 Research
Study: ISB 1442-101
12/20/2024 IGI Inc — — Cash or cash equivalent $521.64 Research
Study: ISB 1442-101
12/20/2024 IGI Inc — — Cash or cash equivalent $521.64 Research
Study: ISB 1442-101
10/30/2024 GlaxoSmithKline, LLC. — Consulting Fee Cash or cash equivalent $16,637.50 General
09/16/2024 IGI Inc — — Cash or cash equivalent $2,250.00 Research
Study: ISB 1442-101
08/08/2024 GlaxoSmithKline, LLC. — Consulting Fee Cash or cash equivalent $1,925.00 General
07/12/2024 IGI Inc — — Cash or cash equivalent $4,982.00 Research
Study: ISB 1442-101
07/12/2024 IGI Inc — — Cash or cash equivalent $2,800.00 Research
Study: ISB 1442-101
07/12/2024 IGI Inc — — Cash or cash equivalent $2,760.00 Research
Study: ISB 1442-101
07/12/2024 IGI Inc — — Cash or cash equivalent $2,760.00 Research
Study: ISB 1442-101
07/12/2024 IGI Inc — — Cash or cash equivalent $2,760.00 Research
Study: ISB 1442-101
07/12/2024 IGI Inc — — Cash or cash equivalent $2,760.00 Research
Study: ISB 1442-101
07/12/2024 IGI Inc — — Cash or cash equivalent $1,650.00 Research
Study: ISB 1442-101
07/12/2024 IGI Inc — — Cash or cash equivalent $1,250.00 Research
Study: ISB 1442-101
07/12/2024 IGI Inc — — Cash or cash equivalent $1,104.00 Research
Study: ISB 1442-101
07/12/2024 IGI Inc — — Cash or cash equivalent $1,104.00 Research
Study: ISB 1442-101
07/12/2024 IGI Inc — — Cash or cash equivalent $1,104.00 Research
Study: ISB 1442-101
07/12/2024 IGI Inc — — Cash or cash equivalent $1,104.00 Research
Study: ISB 1442-101
07/12/2024 IGI Inc — — Cash or cash equivalent $1,035.00 Research
Study: ISB 1442-101
07/12/2024 IGI Inc — — Cash or cash equivalent $228.00 Research
Study: ISB 1442-101
06/07/2024 GENZYME CORPORATION SARCLISA (Biological) Consulting Fee Cash or cash equivalent $831.00 General
Category: Oncology
05/15/2024 GENZYME CORPORATION SARCLISA (Biological) Food and Beverage In-kind items and services $133.49 General
Category: Oncology
04/29/2024 GlaxoSmithKline, LLC. — Consulting Fee Cash or cash equivalent $20,075.00 General
123…8»

Research Studies & Clinical Trials

Study Name Company Amount Records
ISB 1442 Ichnos Sciences Inc. $64,698 26
ISB 1442-101 IGI Inc $40,904 23
NN9924-4221 Novo Nordisk AS $24,300 6
NN9924-4222 Novo Nordisk AS $3,150 2
NN9924-4309 Novo Nordisk AS $3,025 8
NN9924-4257 Novo Nordisk AS $2,475 4
NN9924-4280 Novo Nordisk AS $2,475 4
NN9924-4338 Novo Nordisk AS $2,138 6
NN9924-4223 Novo Nordisk AS $1,800 2
NN9924-4282 Novo Nordisk AS $1,575 2
NN9924-4233 Novo Nordisk AS $1,350 2
NN9535-4269 Novo Nordisk AS $900.00 2
NN9535-4270 Novo Nordisk AS $900.00 1
NN9535-4114 Novo Nordisk AS $675.00 3
NN9924-4224 Novo Nordisk AS $675.00 2
NN9924-4281 Novo Nordisk AS $450.00 1
NN9924-4234 Novo Nordisk AS $225.00 1
NN9388-4606 Novo Nordisk AS $200.00 1

Medicare Billing by Year

Year Procedures Beneficiaries Services Submitted Medicare Paid
2023 35 1,317 25,108 $2.5M $725,502
2022 32 1,104 20,432 $938,673 $283,695
2021 14 445 1,263 $229,520 $72,749
2020 36 1,086 17,734 $1.2M $301,559
Total Patients
3,952
Total Services
64,537
Medicare Billing
$1.4M
Procedure Codes
117

All Medicare Procedures & Services

117 procedure records from CMS Medicare Utilization — Page 1 of 5

HCPCS Description Setting Year Patients Services Charges Medicare Paid Ratio
J9144 Injection, daratumumab, 10 mg and hyaluronidase-fihj Office 2023 36 15,480 $1.6M $588,111 37.3%
99232 Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes Facility 2023 87 464 $97,440 $29,146 29.9%
99214 Established patient office or other outpatient visit, 30-39 minutes Office 2023 104 230 $54,280 $22,389 41.2%
96413 Administration of chemotherapy into vein, 1 hour or less Office 2023 106 193 $114,134 $19,269 16.9%
99213 Established patient office or other outpatient visit, 20-29 minutes Office 2023 96 179 $27,029 $11,608 42.9%
96401 Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle Office 2023 50 139 $44,341 $7,662 17.3%
J9217 Leuprolide acetate (for depot suspension), 7.5 mg Office 2023 12 45 $180,225 $6,020 3.3%
99233 Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes Facility 2023 19 61 $18,774 $5,761 30.7%
99204 New patient office or other outpatient visit, 45-59 minutes Office 2023 36 36 $14,112 $4,707 33.4%
J9041 Injection, bortezomib, 0.1 mg Office 2023 14 980 $97,020 $4,639 4.8%
36415 Insertion of needle into vein for collection of blood sample Office 2023 129 435 $14,353 $3,648 25.4%
38222 Biopsy and aspiration of bone marrow sample for diagnosis Office 2023 20 22 $18,568 $3,043 16.4%
96417 Administration of additional new drug or substance into vein, 1 hour or less Office 2023 31 55 $15,235 $2,776 18.2%
96367 Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less Office 2023 57 121 $24,563 $2,730 11.1%
99222 Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes Facility 2023 24 24 $9,798 $2,493 25.4%
96375 Injection of additional new drug or substance into vein Office 2023 66 201 $28,467 $2,440 8.6%
96365 Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less Office 2023 35 49 $11,025 $2,253 20.4%
96372 Injection of drug or substance under skin or into muscle Office 2023 50 84 $5,796 $892.80 15.4%
96415 Administration of chemotherapy into vein, each additional hour Office 2023 18 35 $6,650 $776.29 11.7%
96411 Administration of additional new drug or substance into vein using push technique Office 2023 11 15 $3,648 $650.85 17.8%
J3489 Injection, zoledronic acid, 1 mg Office 2023 19 88 $9,680 $588.28 6.1%
96402 Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle Office 2023 18 21 $3,171 $559.44 17.6%
99231 Subsequent hospital care with straightforward or low level of medical decision making, per day, if using time, at least 25 minutes Facility 2023 11 14 $1,876 $553.80 29.5%
J1453 Injection, fosaprepitant, 1 mg Office 2023 19 3,750 $18,750 $449.00 2.4%
36591 Collection of blood sample from implanted device Office 2023 17 24 $3,816 $439.95 11.5%
123…5»

About Dr. Mark Schroeder, MD

Dr. Mark Schroeder, MD is a Medical Oncology healthcare provider based in Saint Louis, Missouri. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 05/08/2007. The National Provider Identifier (NPI) number assigned to this provider is 1255544680.

According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Mark Schroeder, MD has received a total of $337,205 in payments from pharmaceutical and medical device companies, with $80,506 received in 2024. These payments were reported across 184 transactions from 20 companies. The most common payment nature is "" ($151,914).

As a Medicare-enrolled provider, Schroeder has provided services to 3,952 Medicare beneficiaries, totaling 64,537 services with total Medicare billing of $1.4M. Data is available for 4 years (2020–2023), covering 117 distinct procedure/service records.

Practice Information

  • Specialty Medical Oncology
  • Location Saint Louis, MO
  • Active Since 05/08/2007
  • Last Updated 04/17/2025
  • Taxonomy Code 207RX0202X
  • Entity Type Individual
  • NPI Number 1255544680

Products in Payments

  • JAKAFI (Drug) $10,123
  • DAURISMO (Drug) $8,975
  • PREVYMIS (Drug) $7,829
  • MOZOBIL (Drug) $6,650
  • Blincyto (Biological) $5,433
  • SARCLISA (Biological) $4,223
  • ELZONRIS (Drug) $3,900
  • XOSPATA (Drug) $3,650
  • RYBELSUS (Drug) $3,375
  • Ozempic (Drug) $3,363
  • DARZALEX (Biological) $2,399
  • Leukine (Drug) $2,105
  • Doptelet (Drug) $1,377
  • Tresiba (Drug) $450.00
  • Rybelsus (Drug) $225.00
  • Kyprolis (Biological) $124.84
  • Imbruvica (Drug) $99.00
  • DARZALEX (Drug) $50.00
  • MYLOTARG (Biological) $20.05

Explore

Data Sources

Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.

Medical Oncology Doctors in Saint Louis

Dr. Brad Kahl, Md, MD

Medical Oncology — Payments: $379,829

Medical Oncology $379,829

Dr. Russell Pachynski, Md, MD

Medical Oncology — Payments: $362,594

Medical Oncology $362,594

Dr. Ravi Vij, Md, MD

Medical Oncology — Payments: $262,216

Medical Oncology $262,216

Dr. Douglas Adkins, Md, MD

Medical Oncology — Payments: $166,184

Medical Oncology $166,184

Dr. Camille Abboud, Md, MD

Medical Oncology — Payments: $155,687

Medical Oncology $155,687

Dr. Daniel Morgensztern, Md, MD

Medical Oncology — Payments: $85,107

Medical Oncology $85,107